L. Boteju

发表

Explosion with sodium azide [1]

V. Hruby, L. Boteju, G. Li, 1993 .

A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer

Wei Zhang, L. Miller, U. Topaloglu, 2017 .

beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity.

V. Hruby, M. Hadley, C. Haskell-Luevano, 1997, Journal of medicinal chemistry.

Topographical modification of melanotropin peptide analogues with beta-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities.

V. Hruby, T. Yamada, I. Gantz, 1995, Journal of Medicinal Chemistry.

Development and validation of an LC-MS/MS method for determination of a novel anticancer agent (CPI-613) in human plasma.

T. Voelker, L. Boteju, Asela Boteju, 2022, Bioanalysis.

Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932).

Alan G. E. Wilson, W. K. Sonnenburg, D. Augeri, 2010, Journal of medicinal chemistry.

In vitro and in vivo metabolism of a novel antimitochondrial cancer metabolism agent, CPI-613, in rats and human

K. Kassahun, V. Reddy, A. Sheldon, 2022 .

3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.

T. Blackburn, B. Lagu, H. Akunne, 2006, Journal of medicinal chemistry.

Stereoselective total synthesis of topographically constrained designer amino acids: 2′, 6′-dimethyl-β-methyltyrosines

V. Hruby, L. Boteju, K. Russell, 1995 .

Asymmetric synthesis of unusual amino acids: Synthesis of optically pure isomers of N-indole- (2-mesitylenesulfonyl)-β-methyltryptophan

V. Hruby, L. Boteju, X. Qian, 1994 .

Asymmetric synthesis of unusual amino acids: Synthesis of the optically pure isomers of indole-protected β-methyltryptophan suitable for peptide synthesis.

V. Hruby, L. Boteju, Kirsten Wegner, 1993 .

The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptor

V. Hruby, G. Nikiforovich, H. Yamamura, 1996, Journal of medicinal chemistry.

Tryptophan-containing 1,5-tetrazole dipeptide analogs: Synthesis of Trpψ[CN4]Nle as a cis amide bond surrogate.

V. Hruby, L. Boteju, 1993 .

Tryptophan-norleucine 1,5-disubstituted tetrazoles as cis peptide bond mimics: Investigation of the bioactive conformation of a potent and selective peptide for the cholecystokinin-B receptor

V. Hruby, H. Yamamura, T. Zalewska, 1993 .

Identification and Characterization of Two G Protein-coupled Receptors for Neuropeptide FF*

B. Borowsky, T. Branchek, J. A. Bonini, 2000, The Journal of Biological Chemistry.

Analogues of cholecystokinin 26–33 selective for B-type CCK receptors possess δ opioid receptor agonist activity in vitro and in vivo: Evidence for similarities in CCK-B and δ opioid receptor requirements

V. Hruby, G. Nikiforovich, T. Burks, 1994 .

A new method for the synthesis of the optically pure precursors to β-methyl derivatives of tryptophan, histidine, tyrosine and phenylalanine

V. Hruby, D. Patel, L. Boteju, 1994 .

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.

Wei Zhang, L. Miller, U. Topaloglu, 2017, The Lancet. Oncology.

Identification and Characterization of Two Neuromedin U Receptors Differentially Expressed in Peripheral Tissues and the Central Nervous System*

B. Borowsky, T. Branchek, J. A. Bonini, 2000, The Journal of Biological Chemistry.

Affinity alkylation of hamster hepatic arylamine N-acetyltransferases: isolation of a modified cysteine residue.

H. Cheon, P. E. Hanna, L. Boteju, 1992, Molecular pharmacology.

Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism.

K. Lee, R. Shorr, A. Sheldon, 2011, Drug metabolism letters.

Facile removal of the N-indole-mesitylenesulfonyl protecting group using HF cleavage conditions

V. Hruby, C. Haskell-Luevano, L. Boteju, 1995, Letters in Peptide Science.

Bioactivation of N-hydroxy-2-acetylaminofluorenes by N,O-acyltransferase: substituent effects on covalent binding to DNA.

P. E. Hanna, L. Boteju, 1993, Carcinogenesis.

A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer

Wei Zhang, L. Miller, U. Topaloglu, 2017, The Lancet. Oncology.